Evidence map›Paper›PMID 38045321›Full record

ArticlemedRxiv : the preprint server for health sciences2023

Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants.

Catherine Riou, Jinal N Bhiman, Yashica Ganga, Shobna Sawry, Frances Ayres, Richard Baguma, Sashkia R Balla, Ntombi Benede, Mallory Bernstein, Asiphe S Besethi and 46 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

56 authors at 8 institutions in 2 countries.

Catherine RiouInstitute of Infectious Disease and Molecular Medicine, Division of Medical Virology, Department of Pathology, University of Cape Town, Observatory, South Africa.ORCID 0000-0001-9679-0745
Jinal N BhimanSA MRC Antibody Immunity Research Unit, School of Pathology, University of the Witwatersrand, Johannesburg, South Africa.
Yashica GangaAfrica Health Research Institute, Durban, South Africa.
Shobna SawryWits RHI, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.ORCID 0000-0002-3845-4863
Frances AyresSA MRC Antibody Immunity Research Unit, School of Pathology, University of the Witwatersrand, Johannesburg, South Africa.ORCID 0000-0002-7238-0415
Richard BagumaInstitute of Infectious Disease and Molecular Medicine, Division of Medical Virology, Department of Pathology, University of Cape Town, Observatory, South Africa.
Sashkia R BallaSA MRC Antibody Immunity Research Unit, School of Pathology, University of the Witwatersrand, Johannesburg, South Africa.ORCID 0000-0002-5522-2968
Ntombi BenedeInstitute of Infectious Disease and Molecular Medicine, Division of Medical Virology, Department of Pathology, University of Cape Town, Observatory, South Africa.ORCID 0000-0002-3319-8215
Mallory BernsteinAfrica Health Research Institute, Durban, South Africa.ORCID 0000-0001-7498-2391
Asiphe S BesethiInstitute of Infectious Disease and Molecular Medicine, Division of Medical Virology, Department of Pathology, University of Cape Town, Observatory, South Africa.
Sandile CeleAfrica Health Research Institute, Durban, South Africa.
Carol CrowtherSA MRC Antibody Immunity Research Unit, School of Pathology, University of the Witwatersrand, Johannesburg, South Africa.ORCID 0000-0002-0287-7004
Mrinmayee DharWits RHI, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.ORCID 0000-0001-9353-4295
Sohair GeyerInstitute of Infectious Disease and Molecular Medicine, Division of Medical Virology, Department of Pathology, University of Cape Town, Observatory, South Africa.ORCID 0000-0002-8372-6717
Katherine GillThe Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa.ORCID 0000-0002-3372-9506
Alba GrifoniCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, California, USA.
Tandile HermanusSA MRC Antibody Immunity Research Unit, School of Pathology, University of the Witwatersrand, Johannesburg, South Africa.
Haajira KaldineSA MRC Antibody Immunity Research Unit, School of Pathology, University of the Witwatersrand, Johannesburg, South Africa.ORCID 0000-0002-7946-5606
Roanne S KeetonInstitute of Infectious Disease and Molecular Medicine, Division of Medical Virology, Department of Pathology, University of Cape Town, Observatory, South Africa.
Prudence KgagudiSA MRC Antibody Immunity Research Unit, School of Pathology, University of the Witwatersrand, Johannesburg, South Africa.
Khadija KhanAfrica Health Research Institute, Durban, South Africa.
Erica LazarusPerinatal HIV Research Unit, Faculty of Health Science, University of the Witwatersrand, Johannesburg, South Africa.ORCID 0000-0002-4965-0624
Jean Le RouxWits RHI, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.ORCID 0009-0000-7229-3031
Gila LustigCentre for the AIDS Programme of Research in South Africa, University of KwaZulu-Natal, Durban, South Africa.ORCID 0000-0002-8204-0182
Mashudu MadzivhandilaSA MRC Antibody Immunity Research Unit, School of Pathology, University of the Witwatersrand, Johannesburg, South Africa.
Siyabulela Fj MaguguInstitute of Infectious Disease and Molecular Medicine, Division of Medical Virology, Department of Pathology, University of Cape Town, Observatory, South Africa.
Zanele MakhadoSA MRC Antibody Immunity Research Unit, School of Pathology, University of the Witwatersrand, Johannesburg, South Africa.ORCID 0000-0002-8371-6180
Nelia P ManamelaSA MRC Antibody Immunity Research Unit, School of Pathology, University of the Witwatersrand, Johannesburg, South Africa.
Qiniso MkhizeSA MRC Antibody Immunity Research Unit, School of Pathology, University of the Witwatersrand, Johannesburg, South Africa.ORCID 0000-0001-6919-0832
Paballo MosalaInstitute of Infectious Disease and Molecular Medicine, Division of Medical Virology, Department of Pathology, University of Cape Town, Observatory, South Africa.
Thopisang P MotlouSA MRC Antibody Immunity Research Unit, School of Pathology, University of the Witwatersrand, Johannesburg, South Africa.ORCID 0000-0003-4157-4126
Hygon MutavhatsindiInstitute of Infectious Disease and Molecular Medicine, Division of Medical Virology, Department of Pathology, University of Cape Town, Observatory, South Africa.ORCID 0000-0001-6605-6275
Nonkululeko B MzindleSA MRC Antibody Immunity Research Unit, School of Pathology, University of the Witwatersrand, Johannesburg, South Africa.
Anusha NanaPerinatal HIV Research Unit, Faculty of Health Science, University of the Witwatersrand, Johannesburg, South Africa.
Rofhiwa NesamariInstitute of Infectious Disease and Molecular Medicine, Division of Medical Virology, Department of Pathology, University of Cape Town, Observatory, South Africa.
Amkele NgomtiInstitute of Infectious Disease and Molecular Medicine, Division of Medical Virology, Department of Pathology, University of Cape Town, Observatory, South Africa.ORCID 0000-0002-6155-1354
Anathi A NkayiInstitute of Infectious Disease and Molecular Medicine, Division of Medical Virology, Department of Pathology, University of Cape Town, Observatory, South Africa.ORCID 0000-0002-4821-0782
Thandeka P NkosiThe Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa.ORCID 0009-0004-1836-3077
Millicent A OmondiInstitute of Infectious Disease and Molecular Medicine, Division of Medical Virology, Department of Pathology, University of Cape Town, Observatory, South Africa.ORCID 0000-0003-1332-2167
Ravindre PanchiaPerinatal HIV Research Unit, Faculty of Health Science, University of the Witwatersrand, Johannesburg, South Africa.
Faeezah PatelWits RHI, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.ORCID 0000-0003-1503-2016
Alessandro SetteCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, California, USA.ORCID 0000-0001-7013-2250
Upasna SinghCentre for the AIDS Programme of Research in South Africa, University of KwaZulu-Natal, Durban, South Africa.ORCID 0000-0002-7453-3489
Strauss van GraanSA MRC Antibody Immunity Research Unit, School of Pathology, University of the Witwatersrand, Johannesburg, South Africa.ORCID 0000-0003-4506-0763
Elizabeth M VenterSA MRC Antibody Immunity Research Unit, School of Pathology, University of the Witwatersrand, Johannesburg, South Africa.
Avril WaltersInstitute of Infectious Disease and Molecular Medicine, Division of Medical Virology, Department of Pathology, University of Cape Town, Observatory, South Africa.
Thandeka Moyo-GweteSA MRC Antibody Immunity Research Unit, School of Pathology, University of the Witwatersrand, Johannesburg, South Africa.ORCID 0000-0002-4269-9281
Simone I RichardsonSA MRC Antibody Immunity Research Unit, School of Pathology, University of the Witwatersrand, Johannesburg, South Africa.
Nigel GarrettCentre for the AIDS Programme of Research in South Africa, University of KwaZulu-Natal, Durban, South Africa.ORCID 0000-0002-4530-234X
Helen ReesWits RHI, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.ORCID 0000-0003-1442-6734
Linda-Gail BekkerThe Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa.ORCID 0000-0002-0755-4386
Glenda GraySouth African Medical Research Council, Cape Town, South Africa.ORCID 0000-0002-9510-5774
Wendy A BurgersInstitute of Infectious Disease and Molecular Medicine, Division of Medical Virology, Department of Pathology, University of Cape Town, Observatory, South Africa.ORCID 0000-0003-3396-9398
Alex SigalAfrica Health Research Institute, Durban, South Africa.ORCID 0000-0001-8571-2004
Penny L MooreSA MRC Antibody Immunity Research Unit, School of Pathology, University of the Witwatersrand, Johannesburg, South Africa.ORCID 0000-0001-8719-4028
Lee FairlieWits RHI, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.ORCID 0000-0001-5327-1734
National Health Laboratory Service · ZAUniversity of Cape Town · ZAUniversity of the Witwatersrand · ZAAfrica Health Research Institute · ZACentre for the AIDS Programme of Research in South Africa · ZADesmond Tutu HIV Foundation · ZASouth African Medical Research Council · ZALa Jolla Institute for Immunology · US

Funding

LOC: HIV Vaccine Trials NetworkUM1AI068614 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Dan H. Barouch, Lawrence Corey · 2011 to 2026
$1175.6M
NIAID Centers of Excellence for Influenza Research and Response: Universal Influenza Vaccine Research Activities75N93021C00016 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI WEBBY, RICHARD · 2021 to 2025
$91.4M
Large Scale T Cell Epitope Discovery:Global identification of epitopes derived from Zika (ZIKV), Chikungunya (CHIKV) viruses following natural infection and vaccination75N93019C00065 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI MITCHELL, MAYA · 2019 to 2023
$7.3M
NIAID NIH HHS 75N93019C00065NIAID NIH HHS 75N93021C00016NIAID NIH HHS UM1 AI068614Wellcome Trust
6 · The paper itself

Abstract

Background: We report the safety and immunogenicity of fractional and full dose Ad26.COV2.S and BNT162b2 in an open label phase 2 trial of participants previously vaccinated with a single dose of Ad26.COV2.S, with 91.4% showing evidence of previous SARS-CoV-2 infection. Methods: A total of 286 adults (with or without HIV) were enrolled >4 months after an Ad26.COV2.S prime and randomized 1:1:1:1 to receive either a full or half-dose booster of Ad26.COV2.S or BNT162b2 vaccine. B cell responses (binding, neutralization and antibody dependent cellular cytotoxicity-ADCC), and spike-specific T-cell responses were evaluated at baseline, 2, 12 and 24 weeks post-boost. Antibody and T-cell immunity targeting the Ad26 vector was also evaluated. Results: No vaccine-associated serious adverse events were recorded. The full- and half-dose BNT162b2 boosted anti-SARS-CoV-2 binding antibody levels (3.9- and 4.5-fold, respectively) and neutralizing antibody levels (4.4- and 10-fold). Binding and neutralizing antibodies following half-dose Ad26.COV2.S were not significantly boosted. Full-dose Ad26.COV2.S did not boost binding antibodies but slightly enhanced neutralizing antibodies (2.1-fold). ADCC was marginally increased only after a full-dose BNT162b2. T-cell responses followed a similar pattern to neutralizing antibodies. Six months post-boost, antibody and T-cell responses had waned to baseline levels. While we detected strong anti-vector immunity, there was no correlation between anti-vector immunity in Ad26.COV2.S recipients and spike-specific neutralizing antibody or T-cell responses post-Ad26.COV2.S boosting. Conclusion: In the context of hybrid immunity, boosting with heterologous full- or half-dose BNT162b2 mRNA vaccine demonstrated superior immunogenicity 2 weeks post-vaccination compared to homologous Ad26.COV2.S, though rapid waning occurred by 12 weeks post-boost. Trial Registration: South African National Clinical Trial Registry (SANCR): DOH-27-012022-7841. Funding: South African Medical Research Council (SAMRC) and South African Department of Health (SA DoH).

Identifiers

PMID38045321
PMCPMC10690356
OpenAlexW4388859290

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.